Denosumab Effect on Bone Quality and Function After Lumbar Fusion Surgery

Osteopenia Clinical Trial

Official title:

Denosumab Protects Bone Loss and Function in Osteopenia Patients With Lumbar Degenerative Diseases After Lumbar Fusion Surgery, a Randomized, Placebo Controlled Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05415657
• Other study ID #: ShenzhenPH spine01
• Status: Completed
• Phase: N/A
• Start date: January 12, 2020
• Est. completion date: January 10, 2023

Study information

• Verified date: December 2022
• Source: Shenzhen People's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Degenerative lumbar spinal diseases have become a common health problem and the most frequent indication for spinal surgery in elderly individuals. It mainly contain lumbar spinal stenosis and spondylolisthesis, occurs in most people over 60 years of age, and patients primarily diagnosed with lumbar degenerative disease are more likely to have osteoporosis. Our study was to explore denosumab effect on bone quality and functional status in osteopenia patients with lumbar degenerative diseases after lumbar fusion surgery.

Description:

However, It was still unknown for denosumab effect on osteopenia patients after lumbar fusion. Bone mineral density(BMD), bone turnover marker, lumbar functional status Roland-Morris Disability Functioning Questionnaire (RMDQ) and quality of life EuroQol Five-Dimension (EQ-5D), and Quality of Life Questionnaire of the European Foundation for Osteoporosis-31 (QUALEFFO-31) score, rate of new fracture, re-operation, lumbar fusion, complications or adverse events were still unknown. Our study will explore the effect of denosumab on lumbar, total hip, femoral neck BMD and bone turnover markers, functional status EQ-5D, QUALEFFO-31 and RMDQ score of participants after lumbar fusion at 12 months follow-up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 76
• Est. completion date: January 10, 2023
• Est. primary completion date: January 5, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 85 Years

Eligibility

Inclusion Criteria:

• Participants aged 40 to 85 years
• who diagnosed with lumbar spinal stenosis or lumbar spondylolisthesis
• osteopenia with BMD T score between -1.0 and -2.5 via dual-energy X-ray
• low back pain or leg numbness or weakness
• MRI demonstrated signs of nerve compression

Exclusion Criteria:

• cauda equina syndrome
• progressive neurologic deficit
• history of cancer
• scoliosis greater than 15°
• back open surgery history
• have contraindications for surgery
• who had anti-osteoporosis medication within 6 weeks

Related Conditions & MeSH terms

• Bone Diseases, Metabolic
• Osteopenia
• Spine Fusion

Intervention

Drug:
• Denosumab
Denosumab 60 mg per 6 month were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
• Placebo
Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.

Locations

Country	Name	City	State
China	ShenzhenPH	Shenzhen	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Shenzhen People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lumbar bone mineral density (BMD)	Lumbar vertebral (L1 to L4, except the surgery segment) BMD were determined at baseline, 6 and 12 months via Dual-energy X-ray.	up to 12 months
Primary	Total hip BMD	Total hip BMD were determined at baseline, 6 and 12 months via Dual-energy X-ray.	up to 12 months
Primary	Femoral neck BMD	Femoral neck BMD were determined at baseline, 6 and 12 months via Dual-energy X-ray.	up to 12 months
Primary	Type 1 n-terminal propeptide P1NP	Bone formation marker, type 1 n-terminal propeptide P1NP were determined at baseline, 6 and 12 months after surgery.	up to 12 months
Primary	C-terminal crosslinking type 1 collagen terminal peptide CTX	Bone resorption marker, C-terminal crosslinked type 1 collagen terminal peptide, CTX were assessed at baseline, 6 and 12 months after surgery.	up to 12 months
Primary	Visual analog scale (VAS) back	VAS score for back pain were assessed at baseline, 6 and 12 months. Use a ruler about 10cm long, one side is marked with "0" and the other "10" respectively. A score of 0 indicates no pain, 10 indicates the most unbearable pain.	up to 12 months
Primary	VAS leg	VAS score for leg pain were assessed at baseline, 6 and 12 months. Use a ruler about 10cm long, one side is marked with "0" and the other "10" respectively. A score of 0 indicates no pain, 10 indicates the most unbearable pain	up to 12 months
Secondary	EQ-5D quality of life questionnaire	EQ-5D descriptive system is a preference-based quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. From this, a quality of life score can be calculated ranging from -0.594, indicating a health state worse than death where 0 is death, to 1, indicating full health	up to 12 month
Secondary	Roland-Morris Disability Questionnaire	The Roland-Morris Disability Questionnaire is a health status measure designed to be completed by patients to assess physical disability due to low back pain. The lowest score is 0, the highest 24. The higher the score, the more severe the dysfunction.	up to 12 month
Secondary	QUALEFFO-31 Questionnaire	QUALEFFO-31, which contains three domains including pain, physical function, and mental function. The worse the health related quality of life condition, the higher the score. This scale is assessed on a scale of 0 to 100, with 0 indicating the highest QoL and 100 the lowest.	up to 12 month
Secondary	Lumbar Fusion rate	We determined lumbar fusion rate via CT at 12 month after surgery.The lowest rate is 0, the highest 100%. The higher the score represents higher fusion rate.	up to 12 month
Secondary	New fracture rate	New fracture rate including new vertebral fracture and non-vertebral fracture was assessed at 12 month after surgery. The lowest score was 0, the highest score was 100%. The lower score represents no fracture.	up to 12 month
Secondary	Reoperation rate	Reoperation rate was assessed at 12 month after surgery. The lowest reoperation rate was 0, the highest score was 100%.	up to 12 month
Secondary	Complications	Complications such as cage subsidence, pedicle screw loosening, infection, peripheral nerve injury, recurrent symptoms were assessed at 12 months follow-up.	up to 12 month
Secondary	Adverse effect	The main adverse effect including deep vein thrombosis, rash, joint pain, headache, nausea, pneumonia, necrosis of jaw, atypical femoral fracture, pulmonary embolism, transfer to intensive care unit (ICU), stroke, acute renal failure, myocardial infarction and so on.	up to 12 month